Associations Between Improvements in Myelofibrosis (MF) Symptoms and Quality of Life Measures with Splenomegaly Reduction in COMFORT-I: A Randomized, Double-Blind, Phase III Trial of the JAK1 and JAK2 Inhibitor Ruxolitinib Versus Placebo in Patients with MF

被引：4

作者：

Mesa, Ruben A. ^{[1
]}

Gotlib, Jason ^{[2
]}

Gupta, Vikas ^{[3
]}

DiPersio, John F. ^{[4
]}

Catalano, John ^{[5
]}

Deininger, Michael W. ^{[6
]}

Shields, Alan ^{[7
]}

Miller, Carole B. ^{[8
]}

Silver, Richard T. ^{[9
]}

Talpaz, Moshe ^{[10
]}

Winton, Elliott F. ^{[11
]}

Harvey, Jimmie H., Jr. ^{[12
]}

Hare, Thomas ^{[13
]}

Erickson-Viitanen, Sue ^{[13
]}

Sun, William ^{[13
]}

Sandor, Victor A. ^{[13
]}

Levy, Richard S. ^{[13
]}

Kantarjian, Hagop M. ^{[14
]}

Verstovsek, Srdan ^{[14
]}

机构：

[1] Mayo Clin, Scottsdale, AZ USA

[2] Stanford Canc Inst, Palo Alto, CA USA

[3] Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada

[4] Washington Univ, Sch Med, St Louis, MO USA

[5] Frankston Hosp, Frankston, Vic, Australia

[6] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[7] Mapi Values, Boston, MA USA

[8] St Agnes Canc Inst, Baltimore, MD USA

[9] Cornell Univ, Weill Med Coll, New York, NY 10021 USA

[10] Univ Michigan, Ann Arbor, MI 48109 USA

[11] Emory Univ, Sch Med, Atlanta, GA USA

[12] Birmingham Hematol & Oncol Associates, Birmingham, AL USA

[13] Incyte Corp, Wilmington, DE USA

[14] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

BLOOD | 2011年 / 118卷 / 21期

关键词：

D O I：

10.1182/blood.V118.21.3842.3842

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1642 / 1643

页数：2

共 17 条

[1] Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF)
Verstovsek, S.
Mesa, R. A.
Gotlib, J. R.
Levy, R. S.
Gupta, V.
DiPersio, J. F.
Catalano, J.
Deininger, M.
Miller, C. B.
Silver, R. T.
Talpaz, M.
Winton, E. F.
Harvey, J. H.
Vaddi, K.
Erickson-Viitanen, S. K.
Koumenis, I.
Sun, W.
Sandor, V.
Kantarjian, H.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[2] Results Of a Randomized, Double-Blind, Placebo-Controlled Phase III Study (JAKARTA) Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF)
Pardanani, Animesh
Harrison, Claire N.
Cortes, Jorge E.
Cervantes, Francisco
Mesa, Ruben A.
Milligan, Donald
Masszi, Tamas
Mishchenko, Elena
Jourdan, Eric
Vannucchi, Alessandro M.
Drummond, Mark
Jurgutis, Mindaugas
Kuliczkowski, Kazimierz
Gheorghita, Emanuil
Passamonti, Francesco
Neumann, Frank
Gao, Guozhi
Tefferi, Ayalew
BLOOD, 2013, 122 (21)
[3] Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
Srdan Verstovsek
Ruben A. Mesa
Jason Gotlib
Vikas Gupta
John F. DiPersio
John V. Catalano
Michael W. N. Deininger
Carole B. Miller
Richard T. Silver
Moshe Talpaz
Elliott F. Winton
Jimmie H. Harvey
Murat O. Arcasoy
Elizabeth O. Hexner
Roger M. Lyons
Ronald Paquette
Azra Raza
Mark Jones
Deanna Kornacki
Kang Sun
Hagop Kantarjian
Journal of Hematology & Oncology, 10
[4] A Global, Phase 3, Randomized, Double-Blind Study to Evaluate Safety and Efficacy of Selinexor, an XPO-1 Inhibitor, in Combination with Ruxolitinib in JAK Inhibitor-Naive Myelofibrosis (XPORT-MF-034)
Maher, Keri
Rampal, Raajit K.
Bose, Prithviraj
Podoltsev, Nikolai A.
Harrison, Claire N.
Hong, Junshik
Wang, Xulong
Chamoun, Kamal
Mascarenhas, John
BLOOD, 2023, 142
[5] Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
Verstovsek, Srdan
Mesa, Ruben A.
Gotlib, Jason
Gupta, Vikas
DiPersio, John F.
Catalano, John V.
Deininger, Michael W. N.
Miller, Carole B.
Silver, Richard T.
Talpaz, Moshe
Winton, Elliott F.
Harvey, Jimmie H., Jr.
Arcasoy, Murat O.
Hexner, Elizabeth O.
Lyons, Roger M.
Paquette, Ronald
Raza, Azra
Jones, Mark
Kornacki, Deanna
Sun, Kang
Kantarjian, Hagop
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10 : 1 - 14
[6] TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial
Forman, Seth B.
Pariser, David M.
Poulin, Yves
Vincent, Michael S.
Gilbert, Steven A.
Kieras, Elizabeth M.
Qiu, Ruolun
Yu, Dahong
Papacharalambous, Jocelyne
Tehlirian, Christopher
Peeva, Elena
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2020, 140 (12) : 2359 - +
[7] Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF): Updated Results from the Randomized, Placebo-Controlled, Phase III JAKARTA Trial
Pardanani, Animesh
Tefferi, Ayalew
Masszi, Tamas
Mishchenko, Elena
Drummond, Mark W.
Jourdan, Eric
Vannucchi, Alessandro M.
Jurgutis, Mindaugas
Ribrag, Vincent
Rambaldi, Alessandro
Koh, Liang Piu
Rose, Shelonitda
Zhang, Jun
Harrison, Claire
BLOOD, 2020, 136
[8] INDEPENDENCE: Enrolling Phase III Trial to Study the Efficacy and Safety of Luspatercept versus Placebo in Patients With Myelofibrosis on JAK2 Inhibitor (JAK2i) Therapy Requiring Red Blood Cell Transfusions (RBCTs)
Kiladjian, Jean-Jacques
Harrison, Claire
Mesa, Ruben A.
Al-Ali, Haifa K.
Mascarenhas, John
Sanabria, Fabian
Buerki, Julie Vienne
Bengoudifa, Bourras-Rezki
Passamonti, Francesco
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S390 - S390
[9] MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib Vs. Placebo and Ruxolitinib in JAK-Inhibitor-Naive Myelofibrosis Patients
Mascarenhas, John
Harrison, Claire
Luptakova, Katarina
Christo, Jessica
Wang, Jing
Mertz, Jennifer A.
Colak, Gozde
Shao, James
Bobba, Suresh
Trojer, Patrick
Senderowicz, Adrian
Humphrey, Jeffrey S.
Verstovsek, Srdan
BLOOD, 2020, 136
[10] MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL STUDY OF CPI 0610 AND RUXOLITINIB VS. PLACEBO AND RUXOLITINIB IN JAK INHIBITOR-TREATMENT-NAIVE MYELOFIBROSIS PATIENTS
Passamonti, F.
Palandri, F.
Mascarenhas, J.
Harrison, C.
Patriarca, A.
Vannucchi, A.
Luptakova, K.
Wang, J.
Colak, G.
Shao, J.
Bobba, S.
Trojer, P.
Humphrey, J.
Verstovsek, S.
HAEMATOLOGICA, 2021, 106 (10) : 81 - 82

← 1 2 →